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A B S T R A C T
Macrophages are highly plastic cells of the innate immune system. Macrophages play central roles in immunity
against microbes and contribute to a wide array of pathologies. The processes of macrophage activation and their
functions have attracted considerable attention from life scientists. Although macrophages are highly resistant to
many toxic stimuli, including oxidative stress, macrophage death has been reported in certain diseases, such as
viral infections, tuberculosis, atherosclerotic plaque development, inﬂammation, and sepsis. While most studies
on macrophage death focused on apoptosis, a signiﬁcant body of data indicates that programmed necrotic cell
death forms may be equally important modes of macrophage death. Three such regulated necrotic cell death
modalities in macrophages contribute to diﬀerent pathologies, including necroptosis, pyroptosis, and partha-
natos. Various reactive oxygen and nitrogen species, such as superoxide, hydrogen peroxide, and peroxynitrite
have been shown to act as triggers, mediators, or modulators in regulated necrotic cell death pathways. Here we
discuss recent advances in necroptosis, pyroptosis, and parthanatos, with a strong focus on the role of redox
homeostasis in the regulation of these events.
1. Introduction
Macrophages (MΦs) are phagocytic cells of the innate immune
system that play central roles in tissue homeostasis and response to
pathogenic stimuli. Circulating monocytes can enter the tissues and
diﬀerentiate into MΦs in response to CSF1 and GM-CSF. On the other
hand, tissue resident MΦs (e.g. Kupﬀer cells in the liver and brain mi-
croglia) have been shown to arise from yolk sac-derived (and not bone
marrow-derived) primitive MΦs and settle in organs prenatally [1,2] or
may even transdiﬀerentiate from smooth muscle cells, as demonstrated
in the wall of atherosclerotic arteries [3].
In tissues, MΦs sample the environment and respond to the pa-
thogen- or damage-associated molecular patterns (PAMPs and DAMPs,
respectively), toxins, cytokines, and chemokines. Depending on the
composition of the sampled environment, MΦs diﬀerentiate into a
diverse set of phenotypes, which are usually characterized by two ex-
tremes of the MΦ diﬀerentiation spectrum, M1 (inﬂammatory) and M2
(resolutory). However, MΦs are characterized by high plasticity and
their phenotype can easily change in response to alterations of the
microenvironment.
Classically activated (M1-like) MΦs produce large amounts of re-
active oxygen and nitrogen species (ROS and RNS, respectively), mostly
via activation of NADPH Oxidase 2 (NOX2) and inducible nitric oxide
synthase (iNOS). These reactive species are eﬀective tools to combat
pathogens but also contribute to organ damage in inﬂamed tissues. MΦs
also succumb to this ROS and RNS-ﬁlled environment and undergo cell
death. While research on programmed cell death initially focused on
apoptosis, in recent decades several novel forms of programmed ne-
crotic cell death (necroptosis, pyroptosis, parthanatos, oxytosis, fer-
roptosis, NETosis) have attracted increased attention [4]. Many of these
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modalities are relevant to MΦs. Here, we will discuss the mechanisms
and pathological consequences of programmed necrotic cell death of
MΦs focusing on pyroptosis, necroptosis, and parthanatos.
2. Pyroptosis
The term pyroptosis (from Greek “pyro,“- ﬁre or fever, and “ptosis”
– falling) was initially proposed by Cookson and Brennan [5] for a novel
form of inﬂammatory programmed cell death. The ﬁrst observations of
pyroptosis were made with the invasive pathogenic bacteria Shigella
and Salmonella, which triggered lytic cell death by activating caspase-1
in MΦs via the secreted eﬀector proteins, SipB and IpaB, respectively
[6,7]. Initially, this process was incorrectly classiﬁed as apoptosis, but
was subsequently recognized as a form of programmed cell death dif-
ferent from apoptosis.
Pyroptosis is now recognized as its own entity of programmed cell
death. Initially, pyroptosis was described as being dependent on cas-
pase-1 and gasdermin D (GSDMD), discriminating it on the mechanistic
level from other forms of cell death, such as apoptosis, which depends
on caspase-8, and necroptosis, which depends on RIP3 and mixed
lineage kinase domain-like (MLKL) [8]. The prototypical form of pyr-
optosis is triggered by activation of proinﬂammatory caspases (caspase-
1,-4,-5 in man and caspase-1 and -11 in mice). The terminal cell lysis is
then mediated by cleavage of GSDMD by one of these caspases [9,10].
The active form of GSDMD, which consists of an N-terminal domain,
can assemble to form pores in the cell membrane [11,12]. These pores
lead to collapse of the membrane, potentially initiating death of the
cell, but at the same time leading to the release of inﬂammatory med-
iators, including IL-1β and IL-18 [9,10,13]. Compared to apoptosis,
where the cell content of the dying cell is sealed in apoptotic bodies,
this form of cell death is inﬂammatory and the highly inﬂammatory
cytokines of the IL-1 family and cellular danger signals (damage-asso-
ciated molecular pattern - DAMP) are released. Besides GSDMD, other
members of the gasdermin family participate in pyroptotic cell death.
GSDME (DFNA5) cleavage by caspase-3 can induce pyroptosis in cer-
tain cancer cells upon chemotherapy [14], a process termed non-ca-
nonical pyroptosis. GSDMB is highly expressed in septic shock and
might contribute to GSDMD processing [15].
Recently, it was shown that caspase-8 also cleaves GSDMD, leading
to caspase-8-mediated GSDMD-dependent cell death in response to
extrinsic triggers of apoptosis [16]. This form of pyroptosis is induced
by inhibition of pro-survival signals, mainly by pharmaceutical or
bacterial targeting of TAK1 kinase [17–19]. These examples illustrate
that diﬀerent forms of pyroptotic cell death exist and that these are
interconnected with apoptotic and necroptotic pathways.
The main function of the classical pyroptosis pathway is thought to
be defense against infection [12]. Pathogens and pathogen-derived
toxins are sensed by cytosolic pattern-recognition receptors (PRRs).
Pyrin domain (PYD)-containing members of the Nod-like receptor
(NLR) family and AIM2 are the most thoroughly studied members of the
cytosolic PRRs. Upon activation, PYD-containing NLR proteins and
AIM2 form a multimeric high-molecular weight complex in the cell,
containing the adaptor protein apoptosis associated speck-like protein
containing a CARD (ASC). These complexes, named “inﬂammasomes”
by Jürg Tschopp, are scaﬀolds for the activation of pro-caspase-1,
which is induced by proximity induced auto-processing [20]. ASC
consists of a PYD and a CARD domain. The PYD domain can form
homo-oligomeric interactions with the PYD from NLR or AIM2 and the
CARD forms homo-oligomeric interactions with the CARD of caspase-1.
In addition to the recruitment of eﬀector cells by the released cytokines,
one eﬀector mechanism induced by the pyroptotic program is the ex-
pulsion of invaded bacterial pathogens from the aﬀected cell in small
membrane-enclosed structures. These pore-induced intracellular traps
(PIT) can induce eﬀerocytosis of the engulfed material by macrophages
and neutrophils [21].
Currently, ﬁve PRRs are described as sensor proteins that induce
pyroptosis (see Table 1). PRRs, including AIM2, NAIP/NLRC4 oligomer,
NLRP3, Pyrin (TRIM20), and NLRP1, sense a variety of structurally
diﬀerent PAMPs. AIM2 reacts to double-stranded DNA in the cytosol
[22], NAIP/NLRC4 senses bacterial type III secretion apparatus proteins
and ﬂagellin [23], NLRP3 is activated by diﬀerent kinds of membrane
damage [24], Pyrin is activated by bacterial modiﬁcation of host pro-
teins [25], and NLRP1 senses anthrax lethal toxin and Toxoplasma [26].
All of these pathways induce the activation of caspase-1, which ulti-
mately processes GSDMD (Fig. 1). An alternative pathway to activate
pyroptosis is triggered by activation of caspase-11/4/5. This non-ca-
nonical inﬂammasome is activated by cytosolic lipopolysaccharide
(LPS) [27,28]. Caspase-11 in mice and caspase-4 and -5 in man bind to
LPS, leading to activation of these caspases [29]. Although caspase-11/
4/5 can cleave and activate GSDM in human myeloid cells to induce
pyroptosis, IL-1β production upon cytosolic LPS sensing by this
pathway depends on NLRP3 activation [30]. GSDMD cleavage is
Table 1
Pyroptosis inducers (see text for details and references).
Inducer PRR Pathway
cytosolic dsDNA AIM2 Canonical pyroptosis
bacterial type III SA, ﬂagellin NAIP/NLRC4 Canonical pyroptosis
membrane damage NLRP3 Canonical pyroptosis
Bacterial modiﬁcation of GTPases Pyrin Canonical pyroptosis
Anthrax lethal toxin, Toxoplasma ssp. NLRP1 Canonical pyroptosis
Cytosolic LPS Caspase4,5/11 Canonical pyroptosis
Chemotherapy drugs GSDME Non-canonical, caspase-3, GSDME
Targeting of TAK1 Caspase-8-mediated GSDMD cleavage
Fig. 1. Schematic representation of the pyroptosis pathways in a mammalian
cell. See text for details.
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needed to induce activation of NLRP3 [9]. The mechanism of NLRP3
activation is poorly understood; however, GSDMD and GSDME both
target mitochondrial membranes and stimulate the release of ROS,
which can trigger NLRP3 activation [31,32].
Release of the potent inﬂammatory cytokine, IL-1β, is important in
controlling infection. However, IL-1β has detrimental eﬀects in sepsis, a
life-threatening organ dysfunction caused by an overwhelming cytokine
response towards bacterial pathogens. Neutrophils are emerging as
important players in this condition and targeting the modulation of
pyroptosis in neutrophils might be a viable treatment option [33].
3. Redox control of pyroptosis
As eluded to above, the pyroptosome triggering inﬂammasomes can
be activated by microbial substances. In the case of the NLRP3 in-
ﬂammasome, there is good evidence that its activity is also controlled
by the redox state of the cell (for an excellent overview the reader is
referred to Ref. [34]). The presence of ROS, produced by the MΦs upon
microbial insult, was shown to contribute to NLRP3 activation by the
redox sensor thioredoxin-interacting protein (TXNIP) (reviewed in Ref.
[35]). However, the contribution of TXNIP to NLRP3 activation is
controversial, as TXNIP knockout mice were reported to have no defects
in IL-1β production [36]. NADPH oxidase, the enzyme that produces
ROS for an oxidative burst in MΦs, is also not needed for this activation,
as both NADPH oxidase knock out mice and chronic granulomatosis
patients show normal IL-1β production [37–39]. In contrast, several
reports suggest a role for mitochondrial-derived ROS (mitoROS) [40].
In a model of Shiga toxin and LPS-induced cell activation, mitoROS
plays a critical role in IL-1β release and pyroptosis, mediated by both
NLRP3 and GSDMD [31]. The master transcriptional regulator of redox
homeostasis nuclear factor E2-related factor 2 (Nrf2) further con-
tributes to NLRP3 activation and IL-1β secretion is inhibited by Nrf2
silencing [41,42]. The functional mechanism remains elusive, but is
likely to be indirect, as no contribution of Nrf2 to inﬂammasome
complex formation has yet been identiﬁed. The redox status can di-
rectly aﬀect the activity of initiator caspases. Caspase-1 can be regu-
lated by superoxide via reversible oxidation and glutathionylation of
redox-sensitive cysteine residues. Accordingly, depletion of superoxide
dismutase 1 (SOD1) leads to an oxygen-dependent reduction of caspase-
1 activation [43]. For caspase-11, extracellular ROS can induce its ex-
pression and activation, which involves JNK activation [44].
Our knowledge about the ﬁne-tuning of the ﬁnal steps of pyroptosis
is still very fragmentary, but redox status seems to contribute here as
well. ROS have recently been shown to oxidize GSDM, which enhances
GSDM cleavage by caspase-1 [45].
4. Necroptosis
Caspases are the executioner proteins of both apoptosis and pyr-
optosis. In contrast, necroptosis is a caspase-independent necrotic cell
death program regulated by receptor-interacting protein (RIP) kinases.
Necroptosis was initially discovered when cells, stimulated with FasL,
tumor necrosis factor (TNF), or a TNF ligand, were additionally treated
with the pan-caspase inhibitor, Z-VAD-FMK. Necrosis is an un-
programmed cell death and occurs due to an irreversible injury to the
cell. In contrast, necroptosis is programmed and regulated by receptor-
interacting protein kinase 1 (RIPK1) and receptor-interacting protein
kinase 3 (RIPK3) [46]. Most of the current knowledge about necroptosis
is primarily derived from investigating tumor necrosis factor (TNF)
signaling. Engagement of TNF with its cognizant receptor results in the
formation of complex I at the cell membrane. Complex I is composed of
tumor necrosis factor receptor (TNFR)-associated death domain
(TRADD), Fas-associated death domain (FADD), RIPK1, TNFR-asso-
ciated factors (TRAF), and cellular inhibitor of apoptosis protein 1
(cIAP1) and cIAP2. TRAF proteins ubiquinate and stabilize RIP1 at the
plasma membrane, leading to the activation of nuclear factor kappa B
(NFκB) and cell survival [47]. Activation of necroptosis is initiated by
the deubiquitination of RIPK1 by cylindromatosis protein (CYLD),
which dislodges RIPK1 from complex I and forms a complex II with
FADD, TRADD, and caspase-8. Active caspase-8 can cleave RIPK1 and
RIPK3; however, inhibition of caspase-8 facilitates the interaction of
RIPK1 and RIPK3 through their RIP homotypic interaction motives
(RHIM) [48]. The RIP complex induces the phosphorylation of the
pseudokinase mixed-lineage kinase domain-like protein (MLKL)
[49,50]. Phosphorylation of MLKL exposes the amino acid-terminal 4-
helical bundle domain, which forms a pore in the cell membrane by
interacting with negatively charged phospholipids. Pore formation in
the cell membrane ultimately leads to cell death [51]. The pathway
leading to necroptosis has been largely deciphered through the dis-
covery of small molecule inhibitors that block RIPK1 (necrostatin-1)
[52], RIPK3 (GSK′872) [53], and MLKL (necrosulfonamide) [49].
4.1. Necroptosis in MΦs
Necroptosis in MΦs was ﬁrst reported in the second mitochondria-
derived activator of caspase (SMAC) mimetics mediated inhibition of
cellular inhibitor of apoptosis proteins (cIAPs) and the expression of the
caspase inhibitor XIAP in TNF-α stimulated bone marrow-derived MΦs
(BMDMs) [54]. Consistently, inhibition of proteasomes in MΦs, using
PS-341, suppresses the degradation of cIAPs, and, thus, attenuates ne-
croptosis [55]. More recent reports suggest that the expression of pro-
inﬂammatory cytokines is elevated, while RIPK1-dependent cell death
is reduced, during the diﬀerentiation of MΦs and RIPK3-caspase-8 is
important in the diﬀerentiation of MΦs. Resistance to cell death in
diﬀerentiated MΦs is mediated by the p38/MK2 pathway [56].
Necroptosis plays a crucial role in pathophysiology. Unlike apop-
tosis, which is immunologically quiescent, necroptosis results in the
release of cytoplasmic contents, which can activate MΦs during infec-
tion and other sterile inﬂammatory conditions. Atherogenic ligands
stimulate the expression of the necroptotic genes, RIPK3 and MLKL.
Thus, necroptosis occurs in MΦs associated with human atherosclerotic
plaques, which becomes the driver of necrotic core formation in
atherosclerosis [57]. Plant sterols, such as sitosterol, promote athero-
sclerosis by inducing necroptosis in MΦs [58]. Heme released during
hemolysis is also known to induce necroptosis through ROS and TNF
production due to the activation of TLR [59].
On the other hand, bacterial pathogens target MΦs and mitigate
host defense mechanisms by eliminating MΦs via necroptosis. Excess
TNF induces RIPK1-RIPK3-dependent mitochondrial ROS in
Mycobacterium tuberculosis infected MΦs. The authors propose that in-
duction of necroptosis is through the modulation of cyclophilin D that
regulates mitochondrial membrane permeability pore formation and
ceramide synthesis [60]. A similar phenomenon has also been observed
in ischemia-associated oxidative damage wherein p53 associates with
cyclophilin D and opens the mitochondrial permeability transition pore
resulting in necrotic cell death [61]. Mycobacterium tuberculosis also
secretes tuberculosis necrotizing toxin (TNT), a nicotinamide adenine
dinucleotide (NAD+) glycohydrolase that induces necroptosis in in-
fected MΦs. Interestingly, depletion of NAD+ is suﬃcient to induce
necroptosis in MΦs [62]. Loss of NAD+ may also result from PARP
activation, which suggests that necroptosis and parthanatos, which is
reviewed in the next section of the paper, may be linked. Interestingly
in other cellular models, administration of NAD+ decreases oxidative
stress induced by H2O2 and protects cells from necrosis [63].
Other bacterial pathogens are also known to produce toxins that
induce necroptosis in MΦs. For instance, pathogens such as Serratia
marcescens, Listeria monocytogenes, Staphylococcus aureus, Streptococcus
pneumoniae, and uropathogenic Escherichia coli (UPEC) produce pore-
forming toxins that trigger necroptosis and disrupt the cell membrane,
damage mitochondria, decrease ATP, and increase ROS-generation
[64,65]. These ﬁndings demonstrate that the necroptotic death of MΦs
is a major cause of lung pathology in pneumonia. A strain of
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Streptococcus pneumoniae (TIGR4) is able to invade the heart and cause
cardiac damage. Authors have demonstrated that the damage is criti-
cally associated with the necroptotic death of MΦs induced by pneu-
molysin, the toxin produced by the bacteria [66]. Similarly, Yersinia
outer protein J (YopJ) of Yersinia pestis induces necroptotic death in
MΦs, thus allowing the lymphatic spread of the pathogen [67].
Although most studies describe TNFα as the primary factor reg-
ulating necroptosis, TNFα-independent necroptosis upon the activation
of TLRs in MΦs has also been reported [68]. Our ﬁndings demonstrate
that Salmonella enterica ssp. enterica ser. Typhimurium (S. Typhimurium)
promotion of necroptotic death in MΦs is dependent on type I inter-
feron (IFN–I) signaling. IFN-induced inﬂammatory pathology is pre-
dominantly due to necroptosis. Mice lacking the cognate receptor for
IFN-I (IFNAR) showed reduced bacterial burden and pathology asso-
ciated with the infection [69]. IFN–I drives necroptosis through IFN-
stimulated gene factor 3 (ISGF3) signaling, which leads to persistent
expression of STAT1, STAT2, and IRF9. Strikingly, MLKL is one of the
interferon-stimulated genes (ISGs) [70]. Constitutive interferon sig-
naling, such as in autoimmune diseases, primes MΦs to undergo ne-
croptosis by maintaining adequate levels of MLKL [71].
Oxidative stress is a common feature in macrophage necroptosis
induced by pathogens or under sterile inﬂammatory conditions.
Bacterial toxin-stimulated necroptosis is prevented using Coenzyme
Q10 in combination with a RIPK1 inhibitor. Antioxidants have also
been shown to ameliorate heme-induced necroptosis. Moreover, heme
oxygenase 1 (HO-1) reduces oxidative stress and, thus, provides cyto-
protection [59]. The transcription factor, Nrf2, transcriptionally reg-
ulates HO-1 and other cytoprotective genes by binding to cis-acting
antioxidant responsive elements (ARE). Thus, the Nrf2-regulated anti-
oxidative response inhibits heme-induced cell death [72]. More re-
cently, we have provided evidence that IFN-I-regulated RIPK3 activa-
tion sequesters Nrf2 in the cytoplasm by activating PGAM5 during S.
Typhimurium infection. Importantly, pharmacological activation of
Nrf2, using the synthetic triterpenoid compound, CDDO (2-cyano-3,12-
dioxooleana-1,9-dien-28-oic-acid), was able to prevent necroptosis
[73]. Upon TNFα-induced necroptosis, PGAM5 is recruited to the
RIPK1/RIPK3 complex on the outer mitochondrial membrane, where it
triggers Drp1-mediated mitochondrial fragmentation, which is con-
sidered an obligatory step in necroptosis [74]. Intriguingly, RIPK3 has
been shown to regulate mitochondrial metabolism by targeting the
pyruvate dehydrogenase complex [75]. Mitochondrial oxidative stress
associated cell death also coincides with another form of cell death
known as ferroptosis, which is caused by the accumulation of lipid-
based ROS. Expression of glutathione peroxidase, which repairs oxi-
dized lipid species, is also transcriptionally driven by Nrf2. Hence, Nrf2
is known to play a critical role in mitigating ferroptosis [76]. Inhibition
of PARP has also been shown to reduce ROS generation and protect
mitochondria [77,82]. Consistently, we and others have reported that
during Mycobacterium tuberculosis [62] and S. Typhimurium induced
necroptosis in MΦs, NAD+ is depleted [78] and PARP-1 is activated
[69]. Taken together, this evidence suggests that oxidative stress plays a
signiﬁcant part in the execution of necroptosis (Fig. 2).
5. Parthanatos
Parthanatos is a relatively new addition to the growing list of es-
tablished cell death forms. The term parthanatos was coined to reﬂect
the dependence of this cell death pathway on the formation of poly
(ADP-ribose) (PAR), while the second part of the name refers to
Thanatos, the personiﬁcation of death in Greek mythology [79]. The
PAR polymer is synthesized by some poly (ADP-ribose) polymerase
(PARP) enzyme family members (PARP1, PARP2 and tankyrases) and
parthanatos is triggered by the DNA breakage-induced activation of the
founding member of this enzyme family, PARP1. Poly (ADP-ribosyl)
ation (PARylation) of proteins, including PARP1 itself (auto-PARyla-
tion), near the DNA damage site facilitates the recruitment of DNA
repair eﬀector proteins and, thus, contributes to DNA repair. While
PARylation is primarily a survival mechanism, in cells experiencing
excessive DNA damage, high PARylation activity can cause regulated
necrotic cell death. PARP1-mediated cell suicide was ﬁrst described by
Nathan Berger [80] and was thought to result from the depletion of the
enzyme's substrate, NAD+, and, consequently, ATP in the cells. The
signaling pathway for PARP1-mediated cell death, however, proved to
be more complex than a metabolic collapse. Virág et al. demonstrated
that PARP1-mediated cell death displays the features of necrosis
[81,82]. Inhibition of PARP1 (e.g. by PARP inhibitors or inactivation of
PARP1 gene) diverts cells to the “default” apoptotic route [81,82]. Key
features of parthanatos include: a) its independence from caspases [81];
b) mitochondrial membrane depolarization and secondary ROS pro-
duction [82]; c) dependence on calcium signaling [83]; d) in-
dependence from the cytoprotective eﬀect of Bcl-2 [84]; e) synergism
between PARG and PARP1 in cell death regulation [85].
The central mediator of this cell death pathway is the DNA damage
response protein PARP1. PARP1 activation is considered a hallmark of
oxidative stress. As a DNA nick sensor enzyme, PARP1 binds to broken
DNA resulting in its activation. Activated PARP1 cleaves NAD+ into
ADP-ribose and nicotinamide and attaches ADP-ribose to acceptor
proteins near the damage site. The enzyme can add further ADP-ribose
units to the protein proximal moiety to generate an (ADP-ribose)n
polymer known as poly (ADP-ribose) (PAR). PAR polymers are de-
graded by poly (ADP-ribose) glycohydrolase (PARG) and ADP-ribo-
sylhydrolase-3 (ARH3) enzymes [86].
5.1. The canonical route of parthanatos
The fact that PARP1-mediated cell death is now recognized as a
stand-alone cell death entity is mainly due to discoveries made in the
lab of Valina and Ted Dawson at Johns Hopkins University. Their lab
showed that cerebral ischemic injury [87], N-methyl-D-aspartate
(NMDA) excitotoxicity [87], 1-metil-4-fenil-1,2,3,6-tetrahidropiridin
(MPTP)-induced Parkinsonism, and neurodegenerative diseases [88,89]
are mediated by PARP1 activation. While characterizing the molecular
events leading to and following PARP1 activation in excitotoxicity, they
identiﬁed apoptosis-inducing factor (AIF) as the downstream mediator
of cell death [90]. Their proposed model relies on the following key
events of parthanatos: stimulation of the NMDA receptor in neurons,
glutamate triggering of calcium signaling, and calcium-dependent ac-
tivation of the neuronal isoform of nitric oxide synthase (nNOS). Neu-
ronal NOS produces nitric oxide, which combines with superoxide
anion radical to form peroxynitrite (ONOO−). Peroxynitrite is highly
reactive and causes, among other macromolecular damages, DNA
strand breaks [91]. Once DNA breaks are formed, the pathway may
show an overlap with other cell death models in which DNA damage is
triggered by direct DNA damaging stimuli (e.g. treatment with exo-
genous peroxynitrite, hydrogen peroxide, or DNA alkylating or cross-
linking agents). DNA breaks are recognized by PARP1 and the enzyme
becomes activated. Active PARP1 synthesizes the PAR polymer from
NAD+ to mark the site of DNA damage. PARG and ARH3 enzymes
cleave the polymer oﬀ of PARylated proteins and the polymers (whe-
ther protein-bound or “naked” polymers is not known) leave the nu-
cleus and translocate to the mitochondria (Fig. 3). PAR triggers the
release of AIF from the mitochondrial intermembrane space and AIF
begins its journey towards the nucleus [79]. The mechanism of AIF
release is not fully understood. PARP1-mediated NAD+ depletion may
trigger mitochondrial membrane depolarization, facilitating AIF re-
lease. Alternatively, the polymer may directly interact with the C-ter-
minus of membrane-bound AIF. As an alternative to the consumption of
NAD+, suppression of glycolysis may result from PAR binding to and
inhibition of hexokinase, a key regulatory control point of glycolysis.
Either way, AIF leaves the mitochondria and interacts with macrophage
migration inhibitory factor (MIF) in the cytoplasm. Nuclear transloca-
tion of MIF is followed by MIF-mediated DNA fragmentation, as a result
N. Robinson, et al. Redox Biology 26 (2019) 101239
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of the newly discovered nuclease activity of this multifunctional protein
[92].
5.2. Parthanatos in MΦs
Zingarelli et al. [93] was the ﬁrst to demonstrate that PARP1-
mediated cell death is an important cell death modality in activated
MΦs. [Of note, at the time of their investigation PARP1 was the only
Fig. 2. Schematic diagram representing the convergence of necroptotic signaling and oxidative stress.
Fig. 3. Parthanatos. Nuclear mitochondrial crosstalk in parthanatos is triggered by DNA damaging stimuli activating PARP1. PAR synthesized in response to DNA
breaks travels to the mitochondria and induces liberation of AIF. In turn, AIF interacts with MIF and the latter degrades DNA.
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known PARylating enzyme and was referred to as poly (ADP-ribose)
synthase; PARS in this study.] They showed that exposure of murine
peritoneal MΦs or J774 macrophage cells to high concentrations
(10 μg/ml) of LPS triggered a rapid burst of superoxide production and
a slower upregulation of iNOS. As a result, the ideal conditions were
created for ONOO− formation, which triggered the following sequence
of events: DNA breakage - PARP1 activation – NAD+/ATP depletion –
cell death pathway. Follow up in vivo studies showed that inhibition of
this pathway led to reduced organ damage and improved survival in
endotoxemic or septic animals [91,94,95].
TLR ligands, such as LPS, also induce production of inﬂammatory
cytokines, with TNFα considered to be the master cytokine regulator of
inﬂammation [96]. MΦs are not only the primary source of TNFα, but
also important targets of TNFα. MΦs express both TNFα receptors
(TNFR1 and TNFR2) and respond to TNFα stimulation [96]. TNFα
–induced cell death has been shown to be mediated by PARP1 in Ac-
tinomycin D-pretreated L929 and ME-180 human cervical carcinoma
cells, but whether or not MΦs react similarly to the toxic eﬀect of this
cytokine remains to be seen [97].
Cytotoxicity of exogenous DNA damaging agents, such as H2O2, has
also been investigated in MΦs. MΦs are often exposed to reactive
oxygen species and are quite resistant to H2O2, mainly due to the
constitutively active PI3K-Akt pathway [98]. Nonetheless, high con-
centrations of H2O2 cause PARP1-mediated necrosis-like cell death
characterized by plasma membrane permeabilization and lack of cas-
pase activation [99]. Interestingly, even though this cell death is PARP1
dependent, no sign of AIF translocation could be observed. Thus, this
type of cell death showed some key signs of parthanatos (PARP1-de-
pendence, necrotic phenotype, energetic collapse), while lacking other
key features (e.g. AIF translocation). Similar non-canonical parthanatos
could also be observed in other models of cell death [100–102] raising
the question as to which cell death events should be considered es-
sential for the deﬁnition of parthanatos. Based on the above con-
troversy, we propose a less restrictive deﬁnition that deﬁnes partha-
natos simply as PARP1-dependent regulated necrosis.
6. Outlook
Several open questions remain regarding the execution of necrotic
MΦ cell death. The pathways leading to various forms of cell death are
thought to be distinct. However, some evidence suggests that the ne-
crotic cell death modalities discussed in this review could be inter-
linked. Studies have demonstrated that IAPs prevent RIPK3-dependent
necroptosis and IL-1 activation [103,104]. Consistently, loss of XIAP
triggers RIPK3- and caspase-8-driven IL-1β activation and cell death
[105]. Activated MLKL also triggers the NLRP3 inﬂammasome in a cell
intrinsic manner [106]. Staphylococcus toxin-induced necroptosis also
promotes MLKL-NLRP3-mediated inﬂammation [65]. On the other
hand, RIPK3 has also been shown to activate the inﬂammasome in-
dependent of MLKL [107]. These studies provide vital evidence of cross-
talk between necroptosis and pyroptosis. Interestingly, a recent report
demonstrated that the MLKL inhibitor, necrosulfonamide (NSA), which
has been frequently used to prevent necroptosis in cells of human
origin, also inhibits Gasdermin D, the pyroptosis-executioner [108].
Prevention of cell death using NSA has been interpreted as necroptosis,
but it is possible that the drug also inhibited pyroptosis. Therefore, the
existing data using NSA to inhibit necroptosis need to be revisited to
understand if necroptosis and pyroptosis coexist. The simultaneous
existence of multiple forms of necrotic cell death has not been scruti-
nized. For instance, S. Typhimurium infection in macrophages induces
caspase-1/11 activation and IL-1β secretion. Additionally, we have
shown that the pathogen induces necroptosis and also a diﬀerential
PARP-1 cleavage and activation [69]. Similarly, Rhodococcus equi in-
duced necrosis is also associated with PARP-1 activation [109]. PARP-1
activation leads to depletion of NAD+, which is suﬃcient to induce
necroptosis during M. tuberculosis infection in MΦs. These ﬁndings
provoke us to ask if pyroptosis, necroptosis, and parthanatos occur in
diﬀerent subsets of MΦs and how does the mode of cell death switch
from one form to the other, depending on the functional state of the
cell? Moreover, it is increasingly evident that mitochondrial metabo-
lism, as well as glycolytic regulation, is a major contributor to regulated
necrotic cell death modalities in MΦs. Compelling factors that might
link various forms of cell death are reactive oxygen and nitrogen spe-
cies, which sensitize macrophages to necrosis. However, this aspect of
cell death has not yet been investigated in detail. For necroptosis, the
modus operandi of RIP signaling in causing oxidative stress in addition
to MLKL dependent membrane damage requires further investigation.
For pyroptosis, a key question is if cell death related to IL-1 release
can be uncoupled from IL-1 release in the cells. The notion that the
initiation of events of programmed cell death pathways can be revoked
and cells rescued from diﬀerent forms of death is emerging [110]. The
endosomal sorting complexes required for transport (ESCRT) ma-
chinery can repair damaged cell membranes and inhibit cell death
[111], suggesting that this might allow for non-cell death mediated
release of IL-1 cytokines.
As for parthanatos, a detailed molecular characterization of this
death pathway in MΦs, as well as proof for its in vivo relevance, is
missing. Parthanatotic cell death is likely to contribute to inﬂammation
via the release of DAMPs, due to its programmed necrotic phenotype.
The release of the prototypical DAMP protein, HMGB1, is induced by
PARP1 activation [112]. In LPS-treated MΦs, HMGB1 is PARylated,
leading to acetylation, which is essential for HMGB1 release [113]. In
MΦs, the interplay between PARP1 and DAMPs is a two-way commu-
nication. For example, in brain injury, microglial activation is mediated
in part by the release of alarmins from damaged cells. Microglial sig-
naling induced by the alarmin S100B is mediated by PARP1 [114].
Thus, the hypothesis that parthanatos is an inﬂammatory cell death
pathway is plausible. However, the role of parthanatos in various forms
of inﬂammation requires further investigation.
Understanding the regulation of MΦ cell death modalities may open
new avenues for therapeutic interventions in a wide range of in-
ﬂammations ranging from microbial infections and atherosclerosis to
toxic liver injuries. Exploiting our expanding knowledge of MΦ cell
death pathways, the molecular switches diverting cells from one route
to another, and the molecular determinants of MΦ sensitivity to cyto-
toxic stimuli may provide new opportunities for potential clinical
treatments of various inﬂammatory diseases, atherosclerosis, microbial
infections, toxic organ damage, and even cancer.
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